Keywords: Shire, Intuniv, ADHA, USA, FDA, Firazyr, Hereditary angioedema, HAE
Shire gains extended US approval ADHA drug for Intuniv; files response on Firazyr
Article | 02 March 2011
Ireland headquartered specialty drugmaker Shire (LSE: SHP) has received US Food and Drug Administration approved the use of once-daily Intuniv ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
